A new bill, the Breakthrough Therapies Act, would encourage the reclassification of MDMA and psilocybin from schedule I to schedule II drugs.
Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments.
Nona will offer access to its technologies and antibody generation services to Dragonfly for the targets chosen by the latter.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.
